Merck Reports Results Of Phase III Study Of Investigational Oral Allergy Immunotherapy Tablet (AIT) In Patients Ages 5-17 With Grass Pollen Allergy
Links shared publicly online about this topic.
- 1,339total visits
Merck Reports Results Of Phase III Study Of Investigational Oral Allergy Immunotherapy Tablet (AIT) In Patients Ages 5-17 With Grass Pollen Allergy
In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass
View full resource at medicalnewstoday.com
Tags: Allergies, Children's Health, Merck & Co.
Most Recently Shared on March 4, 2010 at 3:12 pm By:
Merck Reports Results Of Phase III Study Of Investigational Oral Allergy Immunotherapy Tablet (AIT) In Patients Ages 5... http://mnt.to/3yrX
Also Shared By:
Advertisement
MNT Allergy News
@mnt_allergy
Merck Reports Results Of Phase III Study Of Investigational Oral Allergy Immunotherapy Tablet (AIT) In Patients Ages 5... http://mnt.to/3yrX
1 year ago...